

Michael Rudnicki, MD, FASN, Priv.-Doz.



Date of birth September 10th, 1973
Place of birth Warsaw, Poland
Nationality Austrian
Affiliation Medical University Innsbruck
Dept. of Internal Medicine IV – Nephrology and Hypertension
Anichstrasse 35
6020 Innsbruck, Austria
Phone +43 512 504 81337 (office)
Email michael.rudnicki@i-med.ac.at, michael.rudnicki@tirol-kliniken.at
ORCID ID 0000-0002-7896-2600

Since 09/2023	Chairman of the Austrian Society of Nephrology
Since 2021	ERKNet Postgraduate Curriculum in Rare Kidney Diseases
2018	Designation of the Centre for Rare Kidney Diseases Innsbruck as an Associated National Centre of the European Reference Networks (ERN - ERKNet) by the Federal Ministry Republic of Austria (Labour, Social Affairs, Health, and Consumer Protection) and by the European Commission
Since 2017	Head of the Peritoneal Dialysis Unit at the Dept. of Internal Medicine IV – Nephrology, Medical University Innsbruck
01-10/2017	Diploma in Genetics (Austrian Medical Association)
Since 2015	Board member of the Austrian Society of Nephrology (ÖGN)
Since 2015	Head of the Rare Kidney Disease Unit at the Dept. of Internal Medicine IV – Nephrology, Medical University Innsbruck
11/2013	Habilitation (postdoctoral qualification): "Systembiologic Analyses of Renal Genexpression in Stable and Progressive Chronic Kidney Diseases"
02-03/2012	Visiting scientist/clinician at the Dept. of Nephrology and Dialysis at the Ospedali Riuniti di Bergamo, Italy, Dir. Prof. Giuseppe Remuzzi
02/2010	FASN – Fellow of the American Society of Nephrology
12/2009 until present	Senior Nephrologist (Oberarzt)
11/2009	Certification in Nephrology (Austria)
11/2007-10/2009	Nephrology fellow at the Dept. of Internal Medicine IV - Nephrology and Hypertension at the University Hospital Innsbruck/Medical University Innsbruck
11/2007	Certification in Internal Medicine (Austria)

10/2001-10/2007	Internal Medicine fellow at the Division of Nephrology and at the Dept. of Internal Medicine at the University Hospital Innsbruck/Medical University Innsbruck
08-10/2001	Post-doctoral fellow at the Div. of Nephrology, Innsbruck; visiting scientist at Stanford University School of Medicine, Department of Nephrology, CA, USA.
10/1993-05/2001	Medical School at the University of Vienna, Austria
12/1994-02/1999	Technician at the research laboratories of the Div. of Nephrology at the University Hospital of Vienna

Research experience: basic science

2019-2022	(Austrian) Principal Investigator of the FWF funded multi-center ERA PerMed project: "PersTlgAN: Personalized Treatment in IgA Nephropathy"
2010-2012	Principal Investigator of the collaborative research project "PD-associated peritonitis – epidemiology and risk factors in Austrian centers"
2009-2014	Co-Investigator of the collaborative large scale integrating research project funded by the EU: " <i>Systems Biology towards Novel Chronic Kidney Disease Diagnosis and Treatment (SysKid)</i> ", grant no. HEALTH-F2-2009-241544
2007-2012	Co-Investigator of the research project funded by the Fonds zur Förderung der wissenschaftlichen Forschung (FWF) " <i>Functional significance of gene expression changes associated with renal ageing</i> "
2002-2006	Supervising scientist of the research project funded by the Fonds zur Förderung der wissenschaftlichen Forschung (FWF) " <i>Gene expression pattern in renal tubular epithelial cells obtained from patients with kidney diseases</i> "
08-10/2001	Visiting scientist at Stanford University School of Medicine, Department of Nephrology, CA, USA. Main interest: " <i>Gene expression profiling using cDNA microarrays</i> "
1999-2001	MD-Thesis: " <i>VDJ-recombination, somatic hypermutation, polymerase μ and their potential relationship to the mechanism of chromosomal translocation in follicular lymphoma</i> ", group of Prof.U.Jaeger, Division of Hematology, University of Vienna
1994-1999	Technical research assistant, group Dr.G.Cohen, Division of Nephrology (head: Prof.W.H.Hörl), Department of Internal Medicine III, University of Vienna (<i>main research interest: isolation, characterisation and functional testing of uremic toxins from serum, HD-fluid and PD-fluid from uremic patients</i>)

Research experience: sponsored studies

Efficacy and Safety of Iptacopan (LNP023) in Adult Patients With Atypical Hemolytic Uremic Syndrome Naive to Complement Inhibitor Therapy (**principal investigator**)

A 6-year, Multicentre, Non-interventional, Postauthorization Safety Study for Patients Prescribed Jinarc® for Autosomal Dominant Polycystic Kidney Disease (**principal investigator, national coordinator**)

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Safety and Efficacy of CCX168 (Avacopan) in Patients with ANCA-Associated Vasculitis Treated Concomitantly with Rituximab or Cyclophosphamide/Azathioprin (*sub-investigator*)

Study of Diabetic Nephropathy with Atrasentan (SONAR) NCT01858532 (*sub-investigator*)

A Study to Evaluate the Safety and Efficacy of CCX168 in Subjects With ANCA-Associated Renal Vasculitis NCT01363388 (*principal investigator*)

CONNECT: Evaluation of the Benefits and Risks in Maintenance Renal Transplant Recipients Following Conversion to Nulojix® (belatacept)-based Immunosuppression NCT01820572 (*sub-investigator*)

ARTS-DN: Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy NCT01874431 (*sub-investigator*)

FIND-CKD: Ferric Carboxymaltose Assessment in Subjects With Iron Deficiency Anaemia and Non-dialysis-dependent CKD NCT00994318 (*sub-investigator*)

A multicenter, randomized, placebo-controlled, double-blind study on the efficacy, safety and tolerability of Certican in preventing end-stage renal disease (ESRD) in patients with autosomal dominant polycystic kidney disease (ADPKD) NCT00414440 (*sub-investigator*)

The Effect of Sulodexide in Overt Type 2 Diabetic Nephropathy NCT00130312 (*sub-investigator*)

The Effect of Sulodexide in Patients with Type 2 Diabetes and Microalbuminuria NCT00130208 (*sub-investigator*)

Original manuscripts

80. Windpessl M, Gauckler P, Zitt E, Lhotta K, Ay C, Eller K, Odler B, Neumann I, **Rudnicki M**, Kronbichler A, Saemann MD. General recommendations for the management of glomerular diseases-2023. Wien Klin Wochenschr. 2023 Aug;135(Suppl 5):696-704.

79. **Rudnicki M**, Windpessl M, Eller K, Odler B, Gauckler P, Neumann I, Zitt E, Regele H, Kronbichler A, Lhotta K, Saemann MD. Diagnosis and treatment of glomerular diseases with a membranoproliferative glomerulonephritis (MPGN) pattern of injury. Wien Klin Wochenschr. 2023 Aug;135(Suppl 5):688-695.

78. Odler B, Pollheimer MJ, Kronbichler A, Saemann MD, Windpessl M, Gauckler P, **Rudnicki M**, Zitt E, Neumann I, Lhotta K, Eller K. Diagnostic and therapy of lupus nephritis – 2023. Wien Klin Wochenschr. 2023 Aug;135(Suppl 5):675-687.

77. Odler B, Windpessl M, Eller K, Saemann MD, Lhotta K, Neumann I, Oberseder G, Duftner C, Dejaco C, **Rudnicki M**, Gauckler P, Hintenberger R, Zwerina J, Thiel J, Kronbichler A. Diagnosis and therapy of granulomatosis with polyangiitis and microscopic polyangiitis-2023: consensus of the Austrian society of nephrology (ÖGN) and Austrian society of rheumatology (ÖGR). Wien Klin Wochenschr. 2023 Aug;135(Suppl 5):656-674.

76. Saemann MD, Odler B, Windpessl M, Regele H, Eller K, Neumann I, Rudnicki M, Gauckler P, Kronbichler A, Knechtelsdorfer M. Diagnosis and therapy of membranous nephropathy-2023. Wien Klin Wochenschr. 2023 Aug;135(Suppl 5):648-655.

75. Gauckler P, Zitt E, Regele H, Eller K, Saemann MD, Lhotta K, Neumann I, **Rudnicki M**, Odler B, Kronbichler A, Zschocke J, Windpessl M. Diagnosis and treatment of focal-segmental glomerulosclerosis-2023. Wien Klin Wochenschr. 2023 Aug;135(Suppl 5):638-647.

74. Gauckler P, Regele H, Eller K, Saemann MD, Lhotta K, Zitt E, Neumann I, **Rudnicki M**, Odler B, Kronbichler A, Windpessl M. Diagnosis and treatment of Minimal Change Disease in adults-2023. Wien Klin Wochenschr. 2023 Aug;135(Suppl 5):628-637.

73. Schimpf J, Kronbichler A, Windpessl M, Zitt E, Eller K, Saemann MD, Lhotta K, **Rudnicki M**. Diagnosis and Treatment of IgA Nephropathy-2023. Wien Klin Wochenschr. 2023 Aug;135(Suppl 5):621-627.

72. Knell AI, Böhm AK, Jäger M, Kerschbaum J, Engl A, **Rudnicki M**, Buchwinkler L, Bellmann-Weiler R, Posch W, Weiss G. Virus-Subtype-Specific Cellular and Humoral Immune Response to a COVID-19 mRNA Vaccine in Chronic Kidney Disease Patients and Renal Transplant Recipients. *Microorganisms*. 2023 Jul 5;11(7):1756.
71. Peters B, Beige J, Siwy J, **Rudnicki M**, Wendt R, Ortiz A, Sanz AB, Mischak H, Reich HN, Nasic S, Mahmood D, Persson A, Fernström A, Weiner M, Stegmayr B; PersTlgAN working group. Dynamics of urine proteomics biomarker and disease progression in patients with IgA nephropathy. *Nephrol Dial Transplant*. 2023 Jun 22:gfad125.
70. Denicolò S, Nair V, Leierer J, **Rudnicki M**, Kretzler M, Mayer G, Ju W, Perco P. Assessment of Fibrinogen-like 2 (FGL2) in Human Chronic Kidney Disease through Transcriptomics Data Analysis. *Biomolecules*. 2022 Dec 31;13(1):89.
69. Bösmüller C, Demmelbauer N, Antlanger M, Oppelt P, **Rudnicki M**, Krendl FJ, Messner F, Öfner D, Schneeberger S, Margreiter C. Successful Pregnancy in a Kidney-Pancreas Transplanted Patient on LifeCycle Pharma Tacrolimus (LCPT)-Based Immunosuppression. *Am J Case Rep*. 2022 Nov 26;23:e937386.
68. Stigler J, Buchwinkler L, Solagna CA, **Rudnicki M**, Pirklbauer M, Mayer G, Kerschbaum J. Humoral Immune Response to a Timely Booster mRNA Vaccination in Non-Responders to a Standard Vaccination Schedule against COVID-19 in Kidney Transplant Recipients. *J Clin Med*. 2022 Oct 30;11(21):6439.
67. Ranches G, Zeidler M, Kessler R, Hoelzl M, Hess MW, Vosper J, Perco P, Schramek H, Kummer KK, Kress M, Krogsdam A, **Rudnicki M**, Mayer G, Huettenhofer A. Exosomal mitochondrial tRNAs and miRNAs as potential predictors of inflammation in renal proximal tubular epithelial cells. *Mol Ther Nucleic Acids*. 2022 May 4;28:794-813.
66. Buchwinkler L, Solagna CA, Messner J, Pirklbauer M, **Rudnicki M**, Mayer G, Kerschbaum J. Antibody Response to mRNA Vaccines against SARS-CoV-2 with Chronic Kidney Disease, Hemodialysis, and after Kidney Transplantation. *J. Clin. Med*. 2021 Dec 28;11(1):148.
65. Zhou D, **Rudnicki M**, Chua GT, Lawrance SK, Zhou B, Drew JL, Barbar-Smiley F, Armstrong TK, Hilt ME, Birmingham DJ, Passler W, Auletta JJ, Bowden SA, Hoffman RP, Wu YL, Jarjour WN, Mok CC, Ardoin SP, Lau YL, Yu CY. Human Complement C4B Allotypes and Deficiencies in Selected Cases With Autoimmune Diseases. *Front Immunol*. 2021 Oct 26;12:739430.
64. Garam N, Cserhalmi M, Prohászka Z, Szilágyi Á, Veszeli N, Szabó E, Uzonyi B, Iliás A, Aigner C, Schmidt A, Gaggl M, Sunder-Plassmann G, Bajcsi D, Brunner J, Dumfarth A, Cejka D, Flaschberger S, Flögelova H, Haris Á, Hartmann Á, Heilos A, Mueller T, Rusai K, Arbeiter K, Hofer J, Jakab D, Sinkó M, Szigeti E, Bereczki C, Janko V, Kelen K, Reusz GS, Szabó AJ, Klenk N, Kóbor K, Kojc N, Knechtelsdorfer M, Laganovic M, Lungu AC, Meglic A, Rus R, Kersnik Levart T, Macioniene E, Miglinas M, Pawłowska A, Stompór T, Podracka L, **Rudnicki M**, Mayer G, Rysava R, Reiterova J, Saraga M, Seeman T, Zieg J, Sládková E, Stajic N, Szabó T, Capitanescu A, Stancu S, Tisljar M, Galesic K, Tislér A, Vainumäe I, Windpessl M, Zaoral T, Zlatanova G, Józsi M, Csuka D. FHR-5 Serum Levels and *CFHR5* Genetic Variations in Patients With Immune Complex-Mediated Membranoproliferative Glomerulonephritis and C3-Glomerulopathy. *Front Immunol*. 2021 Sep 10;12:720183.
63. Leierer J, Perco P, Hofer B, Eder S, Dzien A, Kerschbaum J, **Rudnicki M**, Mayer G. Coregulation Analysis of Mechanistic Biomarkers in Autosomal Dominant Polycystic Kidney Disease. *Int J Mol Sci*. 2021 Jun 26;22(13):6885.
62. Kerschbaum J, **Rudnicki M**, Dzien A, Dzien-Bischinger C, Winner W, Heerspink HL, Rosivall L, Wiecek A, Mark PB, Eder S, Denicolò S, Mayer G. Intra-individual variability of eGFR trajectories in early diabetic kidney disease and lack of performance of prognostic biomarkers. *Sci Rep*. 2020 Nov 12;10(1):19743.
61. **Rudnicki M**, Siwy J, Wendt R, Lipphardt L, Koziolk MJ, Maixnerova D, Peters B, Kerschbaum J, Leierer J, Neprasova M, Banasik M, Sanz AB, Perez-Gomez MV, Ortiz A, Stegmayr B, Tesar V, Mischak H, Beige J, Reich HN 11,12 on behalf of the PERSTIGAN working group. Urine Proteomics for Prediction of Disease Progression in Patients with IgA Nephropathy. *Nephrol Dial Transplant*. 2021 Dec 31;37(1):42-52.

60. Gasteiger S, Berchtold V, Bösmüller C, Dostal L, Ulmer H, Bogensperger C, Resch T, **Rudnicki M**, Neuwirt H, Oberhuber R, Cardini B, Scheidl S, Mayer G, Öfner D, Weissenbacher A, Schneeberger S. A Retrospective Propensity Score Matched Analysis Reveals Superiority of Hypothermic Machine Perfusion over Static Cold Storage in Deceased Donor Kidney Transplantation. *J Clin Med*. 2020 Jul 21;9(7):2311.
59. Kronbichler A, Effenberger M, Shin JI, Koppelstätter C, Denicolò S, **Rudnicki M**, Neuwirt H, Soler MJ, Stevens K, Bruchfeld A, Tilg H, Mayer G, Perco P. Is There Decreasing Public Interest in Renal Transplantation? A Google Trends Analysis. *J Clin Med*. 2020 Apr 7;9(4).
58. Kerschbaum J, Bitter S, Weitlaner M, Kienzl-Wagner K, Neuwirt H, Bösmüller C, Mayer G, Schneeberger S, **Rudnicki M**. Arterial Hypertension as a Risk Factor for Reduced Glomerular Filtration Rate After Living Kidney Donation. *J Clin Med*. 2020 Jan 25;9(2).
57. Garam N, Prohászka Z, Szilágyi Á, Aigner C, Schmidt A, Gaggli M, Sunder-Plassmann G, Bajcsi D, Brunner J, Dumfarth A, Cejka D, Flaschberger S, Flögelova H, Haris Á, Hartmann Á, Heilos A, Mueller T, Rusai K, Arbeiter K, Hofer J, Jakab D, Sinkó M, Szigeti E, Bereczki C, Janko V, Kelen K, Reusz GS, Szabó AJ, Klenk N, Kóbor K, Kojc N, Knechtelsdorfer M, Laganovic M, Lungu AC, Meglic A, Rus R, Kersnik-Levart T, Macioniene E, Miglinas M, Pawłowska A, Stompór T, Podracka L, **Rudnicki M**, Mayer G, Rysava R, Reiterova J, Saraga M, Seeman T, Zieg J, Sládková E, Szabó T, Capitanescu A, Stancu S, Tisljar M, Galesic K, Tislér A, Vainumäe I, Windpessl M, Zaoral T, Zlatanova G, Csuka D. Validation of distinct pathogenic patterns in a cohort of membranoproliferative glomerulonephritis patients by cluster analysis. *Clin Kidney J*. 2020; 13(2): 225-234.
56. Garam N, Prohászka Z, Szilágyi Á, Aigner C, Schmidt A, Gaggli M, Sunder-Plassmann G, Bajcsi D, Brunner J, Dumfarth A, Cejka D, Flaschberger S, Flögelova H, Haris Á, Hartmann Á, Heilos A, Mueller T, Rusai K, Arbeiter K, Hofer J, Jakab D, Sinkó M, Szigeti E, Bereczki C, Janko V, Kelen K, Reusz GS, Szabó AJ, Klenk N, Kóbor K, Kojc N, Knechtelsdorfer M, Laganovic M, Lungu AC, Meglic A, Rus R, Kersnik-Levart T, Macioniene E, Miglinas M, Pawłowska A, Stompór T, Podracka L, **Rudnicki M**, Mayer G, Romana Rysava, Reiterova J, Saraga M, Tomáš Seeman, Zieg J, Sládková E, Szabó T, Capitanescu A, Stancu S, Tisljar M, Galesic K, Tislér A, Vainumäe I, Windpessl M, Zaoral T, Zlatanova G, Csuka D. C4 nephritic factor in patients with immune-complex-mediated membranoproliferative glomerulonephritis and C3-glomerulopathy. *Orphanet J Rare Dis*. 2019 Nov 8;14(1):247.
55. Neuwirt H, Leitner-Lechner I, Kerschbaum J, Ertl M, Pöggsteiner F, Pölt N, Mätzler J, Sprenger-Mähr H, **Rudnicki M**, Schratzberger P, Eder IE, Mayer G. Efficacy and Safety of Belatacept Treatment in Renal Allograft Recipients at High Cardiovascular Risk-A Single Center Experience. *J Clin Med*. 2019 Aug 3;8(8).
54. Perco P, Ju W, Kerschbaum J, Leierer J, Menon R, Zhu C, Kretzler M, Mayer G, **Rudnicki M**; Nephrotic Syndrome Study Network (NEPTUNE). Identification of dicarbonyl and L-xylulose reductase as a therapeutic target in human chronic kidney disease. *JCI Insight*. 2019 Jun 20;4(12). pii: 128120.
53. Koppelstätter C, Leierer J, **Rudnicki M**, Kerschbaum J, Kronbichler A, Melk A, Mayer G, Perco P. Computational Drug Screening Identifies Compounds Targeting Renal Age-associated Molecular Profiles. *Comput Struct Biotechnol J*. 2019 Jun 25;17:843-853.
52. Kienzl-Wagner K, Rosales A, Scheidl S, Giner T, Bösmüller C, **Rudnicki M**, Oberhuber R, Margreiter C, Soleiman A, Öfner D, Waldegger S, Schneeberger S. Successful management of recurrent focal segmental glomerulosclerosis. *Am J Transplant*. 2018 Nov;18(11):2818-2822.
51. Zewinger S, Rauen T, **Rudnicki M**, Federico G, Wagner M, Triem S, Schunk SJ, Petrakis I, Schmit D, Wagenpfeil S, Heine GH, Mayer G, Floege J, Fliser D, Gröne HJ, Speer T. Dickkopf-3 (DKK3) in urine identifies patients with progressive chronic kidney disease. *J Am Soc Nephrol*. 2018 Nov;29(11):2722-2733.
50. Lenders M, Neusser L, **Rudnicki M**, Nordbeck P, Canaan-Kühl S, Nowak A, Cybulla M, Schmitz B, Lukas J, Wanner C, Brand S-M, Brand E. Dose-dependent impact of enzyme replacement therapy on anti-drug antibody titers and clinical outcomes in patients with Fabry disease. *J Am Soc Nephrol*. 2018 Nov 1.
49. Loeschenberger B, Niess L, Würzner R, Schwelberger H, Eder IE, Pühr M, Guenther J, Troppmair J, **Rudnicki M**, Neuwirt H. Calcineurin inhibitor induced complement system activation via MAPK signaling is inhibited by SOCS-3. *Eur J Immunol*. 2018 Feb;48(2):330-343.

48. Bösmüller C, Messner F, Margreiter C, **Rudnicki M**, Öllinger R, Öfner D, Schneeberger S, Maglione M. Outcome in Pancreas Grafts After BK Virus Viremia in Simultaneous Pancreas-Kidney Transplants: A Single-Center Case Report. *Transplant Direct*. 2017 Apr 13;3(5):e154.
47. **Rudnicki M**. Rituximab for treatment of membranoproliferative glomerulonephritis and C3 glomerulopathies. *Biomed Res Int*. 2017;2017:2180508.
46. Zanchi C, Macconi D, Trionfini P, Tomasoni S, Rottoli D, Locatelli L, **Rudnicki M**, Vandesompele J, Mestdagh P, Remuzzi G, Benigni A, Zoja C. MicroRNA-184 is a down-stream effector of albuminuria in driving renal fibrosis in rats with diabetic nephropathy. *Diabetologia*. 2017 Jun;60(6):1114-1125.
45. Khurana R, Ranches G, Schafferer S, Lukasser M, **Rudnicki M**, Mayer G, Hüttenhofer A. Identification of urinary exosomal non-coding RNAs as novel biomarkers in Chronic Kidney Disease. *RNA*. 2017 Feb;23(2):142-152.
44. **Rudnicki M**, Mayr JA, Zschocke J, Antretter H, Regele H, Feichtinger RG, Windpessl M, Mayer G, Pölzl G. MELAS Syndrome and Kidney Disease Without Fanconi Syndrome or Proteinuria: A Case Report. *Am J Kidney Dis* 2016 Dec;68(6):949-953.
43. **Rudnicki M**. FSGS Recurrence in Adults after Renal Transplantation. *Biomed Res Int*. 2016;2016:3295618.
42. Leierer J, **Rudnicki M**, Braniff SJ, Perco P, Koppelstaetter C, Mühlberger I, Eder S, Kerschbaum J, Schwarzer C, Schroll A, Weiss G, Schneeberger S, Wagner S, Königsrainer A, Böhmig GA, Mayer G. Metallothioneins and renal ageing. *Nephrol Dial Transplant*. 2016 Sep;31(9):1444-52.
41. **Rudnicki M**, Perco P, D'haene B, Leierer J, Heinzl A, Mühlberger I, Schweibert N, Sunzenauer J, Regele H, Kronbichler A, Mestdagh P, Vandesompele J, Mayer B, Mayer G. Renal microRNA- and RNA-profiles in progressive chronic kidney disease. *Eur J Clin Invest*. 2016 Mar;46(3):213-26.
40. Kronbichler A, Kerschbaum J, Gründlinger G, Leierer J, Mayer G, **Rudnicki M**. Evaluation and validation of biomarkers in granulomatosis with polyangiitis and microscopic polyangiitis. *Nephrol Dial Transplant*. 2016 Jun;31(6):930-6.
39. **Rudnicki M**, Beckers A, Neuwirt H, Vandesompele J. RNA expression signatures and posttranscriptional regulation in diabetic nephropathy. *Nephrol Dial Transplant*. 2015 Aug;30 Suppl 4:iv35-42.
38. Kronbichler A, Gut N, Zwerina J, Neuwirt H, **Rudnicki M**, Mayer G. Extending the spectrum of a chameleon: IgG4-related disease appearing as interstitial nephritis and mimicking anti-neutrophil cytoplasmic antibody-associated vasculitis. *Rheumatology (Oxford)*. 2015 Jul 9.
37. Biegstraaten M, Arngrímsson R, Barbey F, Boks L, Cecchi F, Deegan PB, Feldt-Rasmussen U, Geberhiwot T, Germain DP, Hendriksz C, Hughes DA, Kantola I, Karabul N, Lavery C, Linthorst GE, Mehta A, van de Mheen E, Oliveira JP, Parini R, Ramaswami U, **Rudnicki M**, Serra A, Sommer C, Sunder-Plassmann G, Svarstad E, Sweeb A, Terryn W, Tylki-Szymanska A, Tøndel C, Vujkovic B, Weidemann F, Wijburg FA, Woolfson P, Hollak CE. Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document. *Orphanet J Rare Dis*. 2015 Mar 27;10(1):36.
36. Neuwirt H, Perco P, Kainz A, Mühlberger I, Leierer J, Noppert SJ, Mayer B, Mayer G, **Rudnicki M**. A 3-biomarker-panel predicts renal outcome in patients with proteinuric renal diseases. *BMC Med Genomics*. 2014 Dec 24;7(1):4.
35. Kern G, Mair S, Noppert SJ, Jennings P, Schramek H, **Rudnicki M**, Mueller GA, Mayer G, Koppelstaetter C. Tacrolimus increases nox4 expression in human renal fibroblasts and induces fibrosis-related genes by aberrant tgf-Beta receptor signalling. *PLoS One*. 2014 May 9;9(5):e96377.
34. Kronbichler A, Kerschbaum J, Fernandez-Fresnedo G, Hoxha E, Kurschat CE, Busch M, Bruchfeld A, Mayer G, **Rudnicki M**. Rituximab treatment for relapsing minimal change disease and focal segmental glomerulosclerosis: a systematic review. *Am J Nephrol*. 2014 Apr 15;39(4):322-330.

33. Ruggenti P, Ruggiero B, Cravedi P, Vivarelli M, Massella L, Marasà M, Chianca A, Rubis N, Ene-Iordache B, **Rudnicki M**, Pollastro RM, Capasso G, Pisani A, Pennesi M, Emma F, Remuzzi G. Rituximab in Steroid-Dependent or Frequently Relapsing Idiopathic Nephrotic Syndrome. *J Am Soc Nephrol*. 2014 Apr;25(4):850-63.
32. Bartel T, Bonaros N, Edlinger M, Velik-Salchner C, Feuchtner G, **Rudnicki M**, Müller S. Intracardiac Echo and Reduced Radiocontrast Requirements During TAVR. *JACC Cardiovasc Imaging*. 2014 Mar;7(3):319-20.
31. Kronbichler A, Kerschbaum J **Rudnicki M**. Induction regimens for ANCA-Associated Vasculitis. *N Engl J Med*. 2013 Nov 7;369(19):1864. (comment)
30. Kerschbaum J, Vychytil A, Lhotta K, Prischl FC, Wiesholzer M, Machhold-Fabrizii V, Kopriva-Altfahrt G, Schwarz C, Balcke P, Oberbauer R, Kramar R, König P, **Rudnicki M**. Treatment with oral active vitamin D is associated with decreased risk of peritonitis and improved survival in patients on peritoneal dialysis. *PLoS One*. 2013;8(7):e67836.
29. Kronbichler A, König P, Busch M, Wolf G, Mayer G, **Rudnicki M**. Rituximab in Adult Patients with Multi-Relapsing/Steroid-Dependent Minimal Change Disease and Focal Segmental Glomerulosclerosis: A report of 5 cases. *Wien Klin Wochenschr*. 2013 Apr 27.
28. Zitt E, König M, Vychytil A, Auinger M, Wallner M, Lingenhel G, Schilcher G, **Rudnicki M**, Salmhofer H, Lhotta K. Use of sodium thiosulphate in a multi-interventional setting for the treatment of calciphylaxis in dialysis patients. *Nephrol. Dial. Transplant*. 2013 May;28(5):1232-40.
27. Poelzl G, Ess M, Von der Heidt A, **Rudnicki M**, Frick M, Ulmer H. Concomitant renal and hepatic dysfunctions in chronic heart failure: Clinical implications and prognostic significance. *Eur J Intern Med*. 2013 Mar;24(2):177-82.
26. Kerschbaum J, König P, **Rudnicki M**. Risk Factors Associated with Peritoneal Dialysis-Related Peritonitis. *Int J Nephrol*. 2012;2012:483250.
25. Neuwirt H, Eder I, Puhr M, **Rudnicki M**. SOCS-3 is down-regulated in progressive CKD patients and regulates proliferation in human renal proximal tubule cells in a STAT1/-3 independent manner. *Lab Invest*. 2013 Jan;93(1):123-34.
24. **Rudnicki M**, Perco P, Neuwirt H, Noppert SJ, Leierer J, Sunzenauer J, Eder S, Zoja C, Eller K, Rosenkranz AR, Müller GA, Mayer B, Mayer G. Increased Renal Versican Expression Is Associated With Progression of Chronic Kidney Disease. *PLoS One*. 2012;7(9):e44891.
23. Kirsch AH, Riegelbauer V, Tagwerker A, **Rudnicki M**, Rosenkranz AR, Eller K. The mTOR-inhibitor Rapamycin mediates proteinuria in nephrotoxic serum nephritis by activating the innate immune response. *Am J Physiol Renal Physiol*. 2012 Aug;303(4):F569-75.
22. Hellemons ME, Kerschbaum J, Bakker SJL, Neuwirt H, Mayer B, Mayer G, de Zeeuw D, Lambers Heerspink HJ, **Rudnicki M**. Validity of Biomarkers Predicting Onset or Progression of Nephropathy in Patients with Type 2 Diabetes: A Systematic Review. *Diabet Med*. 2012 May;29(5):567-77.
21. Noppert SJ, Eder S, **Rudnicki M**. Laser-Capture Microdissection of Renal Tubule Cells and Linear Amplification of RNA for Microarray Profiling and Real-Time PCR. *Methods Mol Biol*. 2011;755:257-66.
20. Kerschbaum J, König P, Hausdorfer J, Mayer G, **Rudnicki M**. Sevelamer use and incidence of peritonitis in peritoneal dialysis. *Wien Klin Wochenschr*. 2011 Mar 28.
19. **Rudnicki M**, Kerschbaum J, Hausdorfer J, Mayer G, Koenig P. Risk factors for peritoneal dialysis-associated peritonitis: The role of oral active vitamin D. *Perit Dial Int*. 2010 Sep;30(5):541-548.
18. Kopriva-Altfahrt G, König P, Mündle M, Prischl F, Roob JM, Wiesholzer M, Vychytil A; Austrian Study Group for Prevention of Peritoneal Catheter-Associated Infections, Arneitz K, Karner A, Artes R, Wolf E, Auinger M,

Pawlak A, Fraberger J, Hofbauer S, Galvan G, Salmhofer H, Pichler B, Wazel M, Gruber M, Thonhofer A, Hager A, Malajner S, Heiss S, Braunsteiner T, Zweiffler M, König P, **Rudnicki M**, Kogler R, Kohlhauser D, Wiesinger T, Kopriva-Altfahrt G, Moser E, Kotanko P, Loibner H, Nitz H, Miska HJ, Wenzel R, Wölfer M, Mündle M, Breuss H, Hölzl B, Prischl F, Schmekal B, Riener EM, Roob JM, Wonisch W, Vikyda R, Vychytil A, Frank B, Wieser C, Wiesholzer M, Pokorny K. Exit-site care in Austrian peritoneal dialysis centers -- a nationwide survey. *Perit Dial Int*. 2009 May-Jun;29(3):330-9.

17. Schramek H, Sarközi R, Lauterberg C, Kronbichler A, Pirklbauer M, Albrecht R, Noppert SJ, Perco P, **Rudnicki M**, Strutz FM, Mayer G. Neuropilin-1 and neuropilin-2 are differentially expressed in human proteinuric nephropathies and cytokine-stimulated proximal tubular cells. *Lab Invest*. 2009 Sep 7.

16. **Rudnicki M**, Mayer G. Significance of genetic polymorphisms of the renin-angiotensin-aldosterone system in cardiovascular and renal disease. *Pharmacogenomics*. 2009 Mar;10(3):463-76.

15. Hochegger K, **Rudnicki M**, Auinger M, Mark W, Margreiter R, Mayer G, Rosenkranz AR. Fever of unknown origin in renal transplant patients with tacrolimus. *Clin Transplant*. 2009 Aug;23(4):575-9.

14. **Rudnicki M**, Perco P, Enrich J, Eder S, Heininger D, Bernthaler A, Wiesinger M, Sarközi R, Noppert SJ, Schramek H, Mayer B, Oberbauer R, Mayer G. Hypoxia response and VEGF-A expression in human proximal tubular epithelial cells in stable and progressive renal disease. *Lab Invest*. 2009 Jan 12.

13. Sarközi R, Perco P, Hochegger K, Enrich J, Wiesinger M, Pirklbauer M, Eder S, **Rudnicki M**, Rosenkranz AR, Mayer B, Mayer G, Schramek H. Bortezomib-Induced Survival Signals and Genes in Human Proximal Tubular Cells. *J Pharmacol Exp Ther*. 2008 Dec;327(3):645-56.

12. Perco P, Wilflingseder J, Bernthaler A, Wiesinger M, **Rudnicki M**, Wimmer B, Mayer B, Oberbauer R. Biomarker candidates for cardiovascular disease and bone metabolism disorders in chronic kidney disease: a systems biology perspective. *J Cell Mol Med*. 2008 Aug;12(4):1177-87.

11. Hochegger K, Perco P, Enrich J, Mayer B, Mayer G, Rosenkranz AR, **Rudnicki M**. In vitro--transcriptional response of polymorphonuclear leukocytes following contact with different antigens. *Eur J Clin Invest*. 2007 Nov;37(11):860-9.

10. **Rudnicki M**, Eder S, Perco P, Enrich J, Scheiber K, Koppelstätter C, Schratzberger G, Mayer B, Oberbauer R, Meyer TW, Mayer G. Gene expression profiles of human proximal tubular epithelial cells in proteinuric nephropathies. *Kidney Int*. 2007 Feb;71(4):325-35.

9. **Rudnicki M**, Eder S, Schratzberger G, Mayer B, Meyer TW, Tonko M, Mayer G. Reliability of t7-based mRNA linear amplification validated by gene expression analysis of human kidney cells using cDNA microarrays. *Nephron Exp Nephrol*. 2004;97(3):e86-95.

8. Cohen G, **Rudnicki M**, Deicher R, Hörl WH. Immunoglobulin light chains modulate polymorphonuclear leucocyte apoptosis. *Eur J Clin Invest*. 2003 Aug;33(8):669-76.

7. **Rudnicki M**, Mayer G. Pharmacogenomics of angiotensin converting enzyme inhibitors in renal disease--pathophysiological considerations. *Pharmacogenomics*. 2003 Mar;4(2):153-62.

6. Cohen G, **Rudnicki M**, Schmaldienst S, Hörl WH. Effect of dialysis on serum/plasma levels of free immunoglobulin light chains in end-stage renal disease patients. *Nephrol Dial Transplant*. 2002 May;17(5):879-83.

5. Nadel B, Marculescu R, Le T, **Rudnicki M**, Böcskör S, Jäger U. Novel insights into the mechanism of t(14;18)(q32;q21) translocation in follicular lymphoma. *Leuk Lymphoma*. 2001 Nov-Dec;42(6):1181-94.

4. Cohen G, **Rudnicki M**, Walter F, Niwa T, Hörl WH. Glucose-modified proteins modulate essential functions and apoptosis of polymorphonuclear leukocytes. *J Am Soc Nephrol*. 2001 Jun;12(6):1264-71.

3. Cohen G, **Rudnicki M**, Hörl WH. Uremic toxins modulate the spontaneous apoptotic cell death and essential functions of neutrophils. *Kidney Int Suppl.* 2001 Feb;78:S48-52.
2. Cohen G, **Rudnicki M**, Hörl WH. Isolation of modified ubiquitin as a neutrophil chemotaxis inhibitor from uremic patients. *J Am Soc Nephrol.* 1998 Mar;9(3):451-6.
1. Cohen G, **Rudnicki M**, Hörl WH. A peptide isolated from a patient on continuous ambulatory peritoneal dialysis has homology to ubiquitin and inhibits the chemotactic response of polymorphonuclear leukocytes. *Miner Electrolyte Metab.* 1997;23(3-6):210-3.

Innsbruck, Austria



Priv.-Doz. Dr. Michael Rudnicki, FASN

13 December 2023